Insulin icodec
Insulin icodec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk. It is currently undergoing Phase 3 trials and expected to be submitted for approval in 2023.[1] It is administered via subcutaneous injection once weekly to help control the blood sugar level of those with diabetes. It has a duration of action that lasts more than eight days (compared to 42 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.[2]
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
The substance is composed of two peptide chains, linked by a disulfide bridge. In addition the 21 amino acid residue chain has two internal disulfide bridges and the second chain is 29 residues long.
References
- "Molecular and Biological Properties of Insulin Icodec*, a New Insulin Analog Designed to Give a Long Half-Life Suitable for Once-Weekly Dosing".
- Kjeldsen TB, Hubálek F, Hjørringgaard CU, Tagmose TM, Nishimura E, Stidsen CE, et al. (July 2021). "Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans". Journal of Medicinal Chemistry. 64 (13): 8942–8950. doi:10.1021/acs.jmedchem.1c00257. PMID 33944562. S2CID 233718893.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.